ArticleJournal of clinical laboratory analysis2022
CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/DNMT3A axis.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Circ-MAP4K3 promotes papillary thyroid cancer progression by sponging miR-758-3p to enhance RRM2 expression.Clinical and experimental medicine · 2026Article
- The critical role of ferroptosis in thyroid cancer development and potential therapeutic implications.Frontiers in oncology · 2026Review
- RETRACTION: CircPTPRM Accelerates Malignancy of Papillary Thyroid Cancer via miR-885-5p/DNMT3A Axis.Journal of clinical laboratory analysis · 2026Article
- Upregulation of lncRNA SSTR5-AS1 promotes osteoblast differentiation and reduces apoptosis.Journal of orthopaedic surgery and research · 2025Article
- Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma.Current issues in molecular biology · 2025Article
- The regulatory network of epithelial-mesenchymal transition-associated non-coding RNAs in thyroid cancer: molecular mechanisms, clinical implications, and therapeutic strategies.Frontiers in oncology · 2025Review
- Unraveling the landscape of m6A RNA methylation in wound healing and scars.Cell death discovery · 2024Review
- The evolving process of ferroptosis in thyroid cancer: Novel mechanisms and opportunities.Journal of cellular and molecular medicine · 2024Review
- Emerging roles of circular RNAs in regulating the hallmarks of thyroid cancer.Cancer gene therapy · 2024Review
- DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression.Functional & integrative genomics · 2024Article
- The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.International journal of general medicine · 2024Article
- The emerging modulators of non-coding RNAs in diabetic wound healing.Frontiers in endocrinology · 2024Review
- CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/DNMT3A axis.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircular RNAs (circRNAs) are implicated in carcinogenesis, including papillary thyroid cancer (PTC). Despite of previous reports regarding the high expression of circPTPRM in PTC, the role and regulatory mechanism remain to be investigated.
methodsCircPTPRM and miR-885-5p expression were examined, and the effects on cell proliferation, migration, and invasion were also measured. Immunoblotting was performed to evaluate DNA methyltransferase 3A (DNMT3A) and the epithelial-mesenchymal transition (EMT)-associated proteins.
resultsCircPTPRM was overexpressed in PTC tissues and cell lines, which predicted poor prognosis. CircPTPRM inhibition significantly alleviated the proliferation, migration, and invasion abilities. It was subsequently confirmed that circPTPRM competed with miR-885-5p for DNMT3A binding. CircPTPRM promoted PTC progression via miR-885-5p/DNMT3A signal axis.
conclusionOur data elucidated that circPTPRM may play an oncogenic role in PTC through circPTPRM/miR-885-5p/DNMT3A axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.